![Liver graphic Liver graphic](/sites/default/files/2024-06/EASL%20SEO%20Teaser%20Card%20Image_1440%20x%20810px.jpg)
June 07, 2024
Results from Phase II MASH trial presented at EASL 2024
![Boehringer inhalers now available at $35 a month for eligible patients Woman with brown hair standing outside in front of blue sky](/sites/default/files/2024-05/Boehringer_Lifestyle_SocialLife_MeetingFriends_1400.jpg)
June 01, 2024
Boehringer inhalers now available at $35 a month for eligible patients
![Pharmacist talking with patient Pharmacist talking with patient](/sites/default/files/2024-05/Quallent-Announcement.jpg)
May 13, 2024
New agreement with Quallent expands biosimilar access
![Improving Access to Clinical Trials Scientists](/sites/default/files/2024-05/Boehringer_Workplace_Lab_Discussion-01_RGB_004.jpg)
May 02, 2024
Improving Access to Clinical Trials
![FDA Approves Additional Formulation of Our Biosimilar Doctor speaking with patient.](/sites/default/files/2024-04/Press%20release%20image_0.jpg)
May 01, 2024
FDA Approves Additional Formulation of Our Biosimilar
![Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline.](/sites/default/files/2024-04/boehringer_biopharmaceutical%20production_Biberach%20resized_0.jpg)
April 16, 2024
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline.
![Results announced from EMPACT-MI phase III trial Scientists working together](/sites/default/files/2024-04/Scientists_working_together.jpg)
April 06, 2024
Results announced from EMPACT-MI phase III trial
![researcher working in a lab photo of male researcher working in a lab](/sites/default/files/2024-03/Boehringer_Workplace_Lab_Research.jpg)
March 19, 2024
New FDA approval for the treatment of GPP
March 12, 2024
Update on sNDA for fibrosing ILD in children and adolescents
![Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month](/sites/default/files/2024-03/Boehringer_Lifestyle_PhysicalActivity_ExercisingOutdoors.jpg)
March 07, 2024
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month
![Top-line Phase II Data for treatment of MASH Liver Illustration](/sites/default/files/2024-03/Survodutide-MASH-Phase-II-Top-Line.jpg)
February 26, 2024
Top-line Phase II Data for treatment of MASH
![photo of female physician in conversation with colleagues](/sites/default/files/us/2023-11/physician-conversation.png)
November 20, 2023
National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)
![photo of researcher](/sites/default/files/us/2023-11/researcher.jpg)
November 10, 2023
Investigational Compound Granted FDA Orphan Drug Designation
![Kidney Illustration](/sites/default/files/us/2023-11/ASi-EMPA-Kidney.png)
November 06, 2023
Promising Phase II Results in Chronic Kidney Disease
![Kidney Illustration](/sites/default/files/us/2023-11/Klinrisk-ASN.jpg)
November 04, 2023
AI-Driven Model Validated to Predict Risk of CKD Progression
![doctor, patient and Rob Base doctor, patient and Rob Base](/sites/default/files/us/2023-11/It-Takes-2-Still_0.jpg)
November 01, 2023
Hip-Hop Classic “It Takes Two” Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease
![two childrens two childrens](/sites/default/files/us/2023-10/Teaser_Press_Release.jpg)
October 30, 2023
Life forward - Boehringer Ingelheim unveils its evolved company brand
![Recipients of the 2023 Prix Galien USA](/sites/default/files/us/2023-11/Prix-Galien-2023.jpg)
October 27, 2023
Boehringer Ingelheim wins 2023 Prix Galien USA
![Physician talking with patient](/sites/default/files/us/2023-09/Cyltezo%20Low%20WAC%20Announcement.jpg)
October 02, 2023
Low-WAC interchangeable biosimilar is now available
![Patient talking to doctor](/sites/default/files/us/2023-09/CKD%20FDA%20Approval_0.jpg)
September 22, 2023
FDA Approved Treatment Option for Adults with CKD
August 28, 2023
Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program
![For download: © 2020, Peter Ginter](/sites/default/files/us/2023-08/HY%202023%20press%20release%20image%20resized_0.jpg)
August 02, 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
![animation of child sitting on couch and smiling with caregiver](/sites/default/files/us/2023-07/snda.jpg)
July 25, 2023
FDA accepts OFEV sNDA for 6–17-year-olds with fibrosing ILD
![Physician talking with patient Physician talking with patient](/sites/default/files/us/2023-07/Cyltezo-ESI-Formulary.jpg)
July 13, 2023
Interchangeable Biosimilar Now on Express Scripts® Formulary
![A graphic showing a person's hand touching a screen with imagery and data A graphic showing a person's hand touching a screen with imagery and data](/sites/default/files/us/2023-07/Effisayil-2-results.png)
July 04, 2023
Boehringer Ingelheim presents Effisayil™ 2 trial results
![Physician talking with patient Physician talking with patient](/sites/default/files/us/2023-07/Cyltezo-Launch-teaser.jpg)
July 01, 2023
Interchangeable biosimilar now available in the U.S.
![Trapped by Uncertainty Trapped by Uncertainty](/sites/default/files/us/2023-07/fit-launch.jpg)
June 28, 2023
Boehringer Ingelheim and FIT Unveil Fifth Piece for The Unwearable Collection
![physician talking with patient physician talking with patient](/sites/default/files/us/2023-06/Cyltezo.jpg)
June 23, 2023
Optum Rx Places Interchangeable Biosimilar on its Commercial Formulary
![DINAMO DINAMO](/sites/default/files/us/2023-06/DINAMO-FDA-Approval.png)
June 21, 2023
FDA approves treatment option for T2D in children 10 and older
![Physician talking with patient Physician talking with patient](/sites/default/files/us/2023-05/Physician%20talking%20with%20patient.jpg)
May 22, 2023
FDA approves autoinjector pen for Interchangeable biosimilar
![Fibroblasts Fibroblasts](/sites/default/files/us/2023-05/AdobeStock_215842808.png)
May 09, 2023
IL-11 inhibitor antibody clinical development launched
![HCP looking at tablet](/sites/default/files/us/2023-05/HCP-looking-at-tablet_0.jpg)
May 02, 2023
U.S. FDA Grants Breakthrough Therapy designation
![Spevigo-J-code Spevigo-J-code](/sites/default/files/us/2023-04/Spevigo-J-code.png)
April 01, 2023
J-Code Issued for SPEVIGO
![Press Release Press Release](/sites/default/files/us/2023-04/Press%20Release.jpg)
March 29, 2023
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
![Preteen boy smiling](/sites/default/files/us/2023-03/preteen-boy-smiling.png)
March 08, 2023
FDA accepts Jardiance sNDA for T2D in children 10 and older
![Healthcare provider and patient at appointment Healthcare provider and patient at appointment](/sites/default/files/us/2023-04/COORDINATE-Diabetes.jpeg)
March 06, 2023
Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines
![The Unwearable Collection Designs](/sites/default/files/us/2023-02/Homepage%20Photo.jpg)
February 28, 2023
Boehringer Ingelheim announces new partnership to support awareness of GPP
![Senior couple laughing on couch](/sites/default/files/us/2023-05/CKD-sNDA.jpg)
January 20, 2023
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease.
![monecules monecules](/sites/default/files/us/2023-01/Teaser_3t.jpg)
January 09, 2023
New cancer therapeutics collaboration with 3T Bio
![New Digital Tx collab with Click New Digital Tx collab with Click](/sites/default/files/us/2023-01/click-tx.png)
December 19, 2022
Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia
December 07, 2022
Full data announced in DINAMO trial in young people with T2D
![Boehringer Ingelheim Welcomes New 2023 GOLD Report Positioning LAMA/LABA as the Preferred Treatment for the Majority of Patients with COPD Hands on a tablet](/sites/default/files/2024-06/Boehringer_Workplace_Office_Teamwork.jpg)
November 16, 2022
Boehringer Ingelheim Welcomes New 2023 GOLD Report Positioning LAMA/LABA as the Preferred Treatment for the Majority of Patients with COPD
November 04, 2022
Full data announced in phase III EMPA-KIDNEY trial
![First patient enrolled in FIBRONEER™-IPF Phase III trial First patient enrolled in FIBRONEER™-IPF Phase III trial](/sites/default/files/us/2023-01/FIBRONEER.png)
October 26, 2022
First patient enrolled in FIBRONEER™-IPF Phase III trial
![New Expanded Access Program for children and adolescents with fibrosing ILD New Expanded Access Program for children and adolescents with fibrosing ILD](/sites/default/files/us/2023-01/EAP.png)
October 17, 2022
Boehringer Ingelheim announces expanded access program
![New Phase III data in children presented at ERS 2022 New Phase III data in children presented at ERS 2022](/sites/default/files/us/2023-01/ERS2022.jpg)
September 25, 2022
Boehringer Ingelheim announces InPedILD PhaseIII trial results
![Photo of Tune In To Lung Health spokesperson Bernie Williams seated at piano, playing guitar and smiling at three women who are affected by interstitial lung disease Photo of Tune In To Lung Health spokesperson Bernie Williams seated at piano, playing guitar and smiling at three women who are affected by interstitial lung disease](/sites/default/files/us/2023-01/TILH.png)
September 21, 2022
Boehringer Ingelheim introduces Tune In To Lung Health
![Lab_tech_conducts_testing](/sites/default/files/us/2023-05/abobe_stock_405830569_0.jpg)
September 01, 2022
FDA approves the first treatment option for generalized pustular psoriasis flares in adults
![Doctor touching a virtual screen with images of VR technology, medication, biotech, stethoscopes, global networks, a cell phone, a laptop, and a patient. There are graphic symbols depicting medicine, health, pharmaceuticals, innovation, research, cardiology, pulmonology, and the words “medical” and “24/7”. Doctor touching a virtual screen with images of VR technology, medication, biotech, stethoscopes, global networks, a cell phone, a laptop, and a patient. There are graphic symbols depicting medicine, health, pharmaceuticals, innovation, research, cardiology, pulmonology, and the words “medical” and “24/7”.](/sites/default/files/us/2023-01/growth.png)
August 03, 2022
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
June 05, 2022
Real-world data announced for adults with type 2 diabetes
![Researcher carries out experiment in laboratory Researcher carries out experiment in laboratory](/sites/default/files/us/2023-01/A-star.png)
June 02, 2022
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies
![Cartoon illustration of pink lungs Cartoon illustration of pink lungs](/sites/default/files/us/2023-01/BI-1015550_ATS-Data.png)
May 15, 2022
Investigational treatment slowed lung function decline in IPF
![New global guidelines for progressive pulmonary fibrosis now available New global guidelines for progressive pulmonary fibrosis now available](/sites/default/files/us/2023-01/Guidelines-PPF_0.png)
May 03, 2022
Boehringer Ingelheim Statement on Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
April 20, 2022
Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care
![Research and development laboratory Research and development laboratory](/sites/default/files/us/2023-01/BI-R-and-D-Investment.png)
April 05, 2022
Boehringer Ingelheim strengthens investment in R&D
March 16, 2022
Phase III EMPA-KIDNEY trial will stop early
![White graphic illustration of lungs White graphic illustration of lungs](/sites/default/files/us/2023-01/BI-1015550_breakthrough.png)
February 24, 2022
FDA Grants Breakthrough Therapy Designation for IPF
December 15, 2021
U.S. FDA grants priority review for spesolimab for the treatment of flares in patients with generalized pustular psoriasis (GPP), a rare, life-threatening skin disease
![newspapers stacked on top of news sign newspapers stacked on top of news sign](/sites/default/files/us/Images/press-release-holding-image02.jpg)
December 13, 2021
Yankees Legend Bernie Williams Teams Up With Multi-Platinum Recording Artist and Actress Jordin Sparks to Unveil New Song Featuring Lyrics From The Breathless® Ballad Challenge Winner
November 16, 2021